Deal Team

Corporate
Finance
Tax

Gilead in its entry into and amendment of agreements with Galapagos NV in its separation into two entities

On January 8, 2025, Galapagos NV (Euronext & NASDAQ: GLPG) announced that it planned to separate into two entities: a newly formed company focused on building a pipeline of innovative medicines through transformational transactions, and its existing company focused on advancing its cell therapy leadership in oncology.  As part of the planned separation, Gilead Sciences, Inc. (NASDAQ: GILD), which holds approximately 25% of the outstanding shares in Galapagos, agreed with Galapagos to amend their existing Option, License and Collaboration Agreement so that it will apply to the new company and cease to apply to Galapagos, and agreed to enter into a royalty agreement with respect to Galapagos.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Gilead.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.